Asset Details
Do you wish to reserve the book?
Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer
Do you wish to request the book?
Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer
2024
Overview
This study aimed to evaluate the safety and efficacy of cisplatin (CDDP) liposomes. A patient with multiple recurrent liver metastases from metastatic nasal carcinoma was administered CDDP liposomes with consent. Magnetic resonance imaging showed that the patient remained stable disease; however, no apparent side effects were observed, and blood draw data showed no worsening of renal function. Patients undergoing partial pancreatectomy and jejunoileal biliary anastomosis for biliary tract cancer who consented to receive CDDP liposomes demonstrated a partial response on angiographic computed tomography; however, they showed slight fatigue. To our knowledge, the present study is the first in Japan to suggest that liposomalization of CDDP may have anticancer effects while alleviating renal damage and bone marrow suppression.
Publisher
Cureus
Subject
